The isocitrate dehydrogenase (IDH) mutation status has been found to be correlated with the prognosis of glioma patients,4, 5, 6 but IDH mutation occurs only in low‐grade gliomas (LGGs) and is not common in higher‐grade glioblastomas (GBM).7 The gene discussed is IDH3A; the disease is central nervous system cancer.